Telangana Targets Rs.1 lakh Cr Investment in Life Sciences: Sridhar Babu
The Minister said the State government has drawn up a comprehensive “Roadmap 2030” to position Telangana as a global life sciences hub
Hyderabad: Telangana has set an ambitious target of attracting `1 lakh crore in new investments in the life sciences sector by 2030, aiming to generate five lakh jobs, IT and industries minister Duddilla Sridhar Babu announced at the AusBiotech International Conference 2025 in Melbourne. The State’s “Roadmap 2030” envisions making Telangana a global hub for Life Sciences through innovation, robust infrastructure, and international partnerships.
Though Telangana ranks 11th in geographical area and 12th in population, it contributes over 5 per cent to India’s GDP. With a GSDP growth of 8.2 per cent in 2024-25 — above the national average of 7.6 per cent — the state has drawn `3.2 lakh crore in investments over the last 20 months, of which `63,000 crore came from life sciences. Exports from the sector touched `26,000 crore between April and December 2024. The government aims to grow the life sciences economy from $80 billion to $250 billion by 2030.
Hyderabad now features in the Global Life Sciences Atlas 2025 alongside Boston, San Francisco and Tokyo — making it the only Indian city on the list. The city’s life sciences office space expanded from 0.6 million sq. ft. in 2022 to 2.4 million sq. ft. in 2024, underscoring rising investor confidence.
Sridhar Babu said the government is nurturing a “ready-to-deploy bio-digital workforce” through the Life Sciences University and Young India Skills University, in collaboration with global organisations like the World Economic Forum. The State promotes innovation under the slogan “Invent in Telangana, not just Make in India,” backed by infrastructure such as Genome Valley and biotech parks.
He invited Australian and global companies to invest in emerging fields like cell and gene therapy, biologics, digital health, and AI-driven drug discovery, highlighting Telangana’s readiness for next-generation biotechnology ventures.
